NCT05786950View on ClinicalTrials.gov

Neural Respiratory Drive of Patients With Chronic Obstructive Pulmonary Disease

NACompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

July 1, 2023

Study Completion Date

September 1, 2024

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany)

inhaled compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany)

Trial Locations (1)

520120

1State Key Laboratory of Respiratory Disease, National clinical research center for respiratory disease, Guangzhou Institute of respiratory health. 2The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Guangzhou Medical University

OTHER